+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032- Product Image
Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032- Product Image
New

Breast Cancer Liquid Biopsy Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 181 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011425
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The breast cancer liquid biopsy market is transforming clinical diagnostics by delivering minimally invasive, real-time testing options for patient monitoring and disease management. As regulatory frameworks, clinical expectations, and innovation cycles shift, senior stakeholders must navigate fast-evolving adoption drivers while addressing operational and commercial imperatives for long-term performance.

Market Snapshot: Breast Cancer Liquid Biopsy

The breast cancer liquid biopsy market increased from USD 702.85 million in 2025 to USD 841.84 million in 2026 and is projected to attain a compound annual growth rate of 20.51%, reaching USD 2.59 billion by 2032. Market expansion is fueled by rising needs for early detection, individualized treatment planning, and continuous disease surveillance. Demand extends across multiple care settings and global regions, reflecting broadening adoption among healthcare systems, laboratories, and clinical practices.

Scope & Segmentation of the Breast Cancer Liquid Biopsy Market

  • Technologies: Prominent platforms include BEAMing, digital PCR, next-generation sequencing (NGS), and both real-time and multiplex quantitative PCR. These methodologies are selected for their balance of sensitivity, sample throughput, and cost—tailored to diverse clinical priorities and workflow demands.
  • Biomarkers: Key analytes measured in this market are circulating free DNA, circulating tumor cells, circulating tumor DNA, and exosomes (such as exosomal RNA and exosomal protein). Each biomarker type delivers unique analytical capabilities and translational relevance for patient care.
  • Applications: The primary clinical uses involve early detection of disease, monitoring of minimal residual disease presence, informing treatment selection, and tracking recurrence. Varied validation requirements and clinical outcomes shape each application’s adoption pathway.
  • Sample Types: Testing protocols utilize plasma, serum, saliva, and urine, with sample selection driven by assay format, patient compatibility, and required analytical sensitivity.
  • End Users: Diagnostic laboratories, hospitals, and research institutes each approach liquid biopsy implementation with distinct regulatory, workflow, and infrastructure considerations.
  • Cancer Stage: Liquid biopsy utilization differs between early-stage and advanced-stage (including metastatic) disease, with variable supporting evidence guiding test use by condition phase.
  • Regions: Americas, Europe/Middle East/Africa, and Asia-Pacific markets display marked differences in regulatory oversight, commercial models, and health system structures. Stakeholders must adapt strategies to local payer expectations and operational norms.

Key Takeaways for Breast Cancer Liquid Biopsy Market Leaders

  • Wider clinical uptake is underpinned by growing confidence in real-time, non-invasive approaches for personalized oncology management.
  • Enhanced assay performance has advanced the reliability of monitoring for minimal residual disease and recurrence scenarios, facilitating more robust use cases.
  • Demonstration of clinical utility relies on the use of multi-center prospective studies and rigorous analytics, which are critical for guideline integration and regulatory positioning.
  • Strategic alliances among diagnostics companies, clinical networks, and academic bodies have become central to accelerating robust real-world evidence gathering.
  • Adaptable commercial models, including centralized and point-of-care laboratory approaches, enable better tailoring to region-specific demand and infrastructure.
  • Segment-level customization—spanning technology selection, biomarker validation, and commercialization tactics—remains important for aligning with clinical end-user requirements.

Tariff Impact on Breast Cancer Liquid Biopsy Diagnostics

Recent changes to tariffs have added complexity to the global supply chain for breast cancer liquid biopsy diagnostics. Higher import duties on reagents and instrumentation are driving both reassessment of procurement strategies and an increased interest in nearshoring. Centralized laboratories may minimize the effects of cost increases through efficiency gains, while decentralized and point-of-care models may experience delays pending the establishment of reimbursement and compelling clinical evidence. Direct supplier renegotiations, dual sourcing, and collaborative industry efforts are needed to manage volatility and ensure long-term resilience.

Methodology & Data Sources

This market assessment integrates primary interviews with clinicians, laboratory executives, diagnostic industry leaders, and regulators, along with a synthesis of current secondary publications, trial registries, and regulatory filings. Findings are confirmed by triangulating real-world case studies with peer-reviewed evidence to support robust strategic planning.

Why This Report Matters

  • Receive actionable recommendations for investing in technology, adapting supply chains, and optimizing commercial models amid shifting policy and reimbursement trends.
  • Gain insight into market segmentation, regional variations, and technology adoption to inform targeted resource allocation and business development.
  • Accelerate implementation with practical guidance for clinical validation, partnership building, and operational execution within rapidly changing regulatory environments.

Conclusion

Coordinating technology investment, clinical validation, and operational agility is essential to capture the opportunities presented by breast cancer liquid biopsy. Strategic execution remains central for ongoing clinical adoption and sustainable market growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Breast Cancer Liquid Biopsy Market, by Technology
8.1. BEAMing
8.2. Digital PCR
8.2.1. Chip Based Digital PCR
8.2.2. Droplet Digital PCR
8.3. Next Generation Sequencing
8.3.1. Targeted Sequencing
8.3.2. Whole Exome Sequencing
8.3.3. Whole Genome Sequencing
8.4. qPCR
8.4.1. Multiplex Quantitative PCR
8.4.2. Real Time Quantitative PCR
9. Breast Cancer Liquid Biopsy Market, by Biomarker Type
9.1. Circulating Free DNA
9.2. Circulating Tumor Cells
9.3. Circulating Tumor DNA
9.4. Exosomes
9.4.1. Exosomal Protein
9.4.2. Exosomal RNA
10. Breast Cancer Liquid Biopsy Market, by Sample Type
10.1. Plasma
10.2. Saliva
10.3. Serum
10.4. Urine
11. Breast Cancer Liquid Biopsy Market, by Cancer Stage
11.1. Advanced Stage
11.1.1. Metastatic Disease
11.2. Early Stage
12. Breast Cancer Liquid Biopsy Market, by Application
12.1. Early Detection
12.1.1. High Risk Screening
12.1.2. Population Screening
12.2. Minimal Residual Disease
12.3. Recurrence Monitoring
12.4. Treatment Selection
13. Breast Cancer Liquid Biopsy Market, by End User
13.1. Diagnostic Laboratories
13.2. Hospitals
13.3. Research Institutes
14. Breast Cancer Liquid Biopsy Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Breast Cancer Liquid Biopsy Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Breast Cancer Liquid Biopsy Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Breast Cancer Liquid Biopsy Market
18. China Breast Cancer Liquid Biopsy Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Adaptive Biotechnologies
19.6. Bio-Rad Laboratories, Inc.
19.7. Biocept, Inc.
19.8. Biodesix, Inc.
19.9. Epic Sciences Inc.
19.10. Exact Sciences Corporation
19.11. Fluxion Biosciences, Inc.
19.12. Grail, LLC
19.13. Guardant Health, Inc.
19.14. Illumina, Inc.
19.15. Menarini Silicon Biosystems
19.16. Myriad Genetics, Inc.
19.17. Natera, Inc.
19.18. NeoGenomics Laboratories
19.19. Qiagen N.V.
19.20. Roche Diagnostics International AG
19.21. Sysmex Inostics GmbH
19.22. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTIPLEX QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REAL TIME QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING FREE DNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY METASTATIC DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH RISK SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POPULATION SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 122. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 123. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 124. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 125. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 142. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 167. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 168. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 169. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 170. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 171. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 172. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 173. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 174. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 175. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 176. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 177. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 178. EUROPE BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 181. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 187. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 188. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 189. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 190. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 192. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 194. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 195. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 196. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 197. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 198. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 199. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 200. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 201. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 202. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 203. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 204. AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 205. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 206. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 207. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 208. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 209. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 210. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 211. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 212. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 213. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 214. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 215. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 216. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 217. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 218. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 219. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 221. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 222. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 223. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 224. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 225. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 226. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 227. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 228. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 229. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 230. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 231. ASEAN BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 232. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 233. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 234. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 235. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 236. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 237. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 238. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 239. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 240. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 241. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 242. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 243. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 244. GCC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 245. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 246. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 247. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 258. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 259. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 260. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 261. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 262. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 263. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 264. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 265. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 266. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 267. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 268. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 269. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 270. BRICS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 271. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 272. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 273. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 274. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 275. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 276. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 277. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 278. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 279. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 280. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 281. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 282. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 283. G7 BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 284. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 285. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 286. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 287. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 288. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 289. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 290. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 291. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 292. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 293. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 294. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 295. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, 2018-2032 (USD MILLION)
TABLE 296. NATO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 297. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 298. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 299. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 300. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
TABLE 301. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
TABLE 302. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QPCR, 2018-2032 (USD MILLION)
TABLE 303. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
TABLE 304. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2032 (USD MILLION)
TABLE 305. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 306. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER STAGE, 2018-2032 (USD MILLION)
TABLE 307. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED STAGE, 2018-2032 (USD MILLION)
TABLE 308. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLIO

Companies Mentioned

The key companies profiled in this Breast Cancer Liquid Biopsy market report include:
  • Adaptive Biotechnologies
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix, Inc.
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • Fluxion Biosciences, Inc.
  • Grail, LLC
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Menarini Silicon Biosystems
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • NeoGenomics Laboratories
  • Qiagen N.V.
  • Roche Diagnostics International AG
  • Sysmex Inostics GmbH
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages181
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 841.84 Million
Forecasted Market Value ( USD ) by 2032 $ 2590 Million
Compound Annual Growth Rate20.5%
Regions CoveredGlobal
No. of Companies Mentioned19

Related Topics

Related Reports

Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast 2025-2032 - Product Image

Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast 2025-2032

  • Report
  • 191 Pages
  • Global
From
Breast Cancer Liquid Biopsy Market Report by Product Services, Circulating Biomarker, End User, and Region 2025-2033 - Product Image

Breast Cancer Liquid Biopsy Market Report by Product Services, Circulating Biomarker, End User, and Region 2025-2033

  • Report
  • 150 Pages
  • Global
From
Liquid Biopsy Market - Global Forecast 2026-2032 - Product Image

Liquid Biopsy Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Competitive Landscape of Liquid Biopsy Market, Forecast by Recent Developments, Strategies, Sustainability Benchmarking, Product Analysis, Key Persons and Revenue - Product Image

Competitive Landscape of Liquid Biopsy Market, Forecast by Recent Developments, Strategies, Sustainability Benchmarking, Product Analysis, Key Persons and Revenue

  • Report
  • 200 Pages
  • Global
From
Fluid Biopsy Market - Global Strategic Business Report - Product Image

Fluid Biopsy Market - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.